<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176198</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-TP-3654-102</org_study_id>
    <nct_id>NCT04176198</nct_id>
  </id_info>
  <brief_title>A Study of Oral TP-3654 in Patients With Myelofibrosis</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, multicenter, dose-escalation, open-label trial to assess safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate&#xD;
      or high-risk primary or secondary MF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll patients who have been previously treated and failed on a JAK&#xD;
      inhibitor or ineligible to receive ruxolitinib or fedratinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the incidence of dose-limiting toxicities (DLTs) at escalated doses of TP-3654</measure>
    <time_frame>28 days</time_frame>
    <description>Frequency, severity, and causal relationship of study defined high grade toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the incidence of treatment emergent adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Frequency, severity, and causal relationship of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of QT interval changes and morphology as assessed by holter electrocardiogram (ECG) monitoring</measure>
    <time_frame>25 hours</time_frame>
    <description>Changes in QT interval and heart rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Half-life (t½)</measure>
    <time_frame>24 hours</time_frame>
    <description>The estimate of time for the TP-3654 concentration or amount to be reduced by half</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Peak Plasma Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>The maximum TP-3654 concentration after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Time of Maximum concentration observed (tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>The estimate of time to maximum TP-3654 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
    <description>The amount of drug exposure over 24 hours period after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess patients for any evidence of Preliminary activity by proportion of patients with responses in complete remission, partial remission, clinical improvement, progressive disease and stable disease</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients achieving objective response by IWG-MRT response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine proportion of patients who have ≥ 25% spleen volume reduction at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients who have ≥ 25% spleen volume reduction compared to baseline after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine proportion of patients who have ≥ 35% spleen volume reduction (SVR35) at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients who have ≥ 35% spleen volume reduction compared to baseline after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine proportion of patients with ≥ 50% improvement in total symptom score (TSS50) at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the reduction in bone marrow fibrosis in repeat biopsies</measure>
    <time_frame>12 months</time_frame>
    <description>Change in bone marrow fibrosis during treatment compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Study potential pharmacodynamic (PD) markers of TP-3654</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate exploratory biomarkers in peripheral blood samples and bone marrow biopsy samples. Change in protein phosphorylation and inflammatory cytokines.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>TP-3654</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-3654</intervention_name>
    <description>Oral PIM Inhibitor</description>
    <arm_group_label>TP-3654</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following inclusion criteria to be eligible:&#xD;
&#xD;
          -  Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET-&#xD;
             MF as per WHO diagnostic criteria and intermediate or high-risk primary or secondary&#xD;
             MF based on the Dynamic International Prognostic Scoring System (DIPSS)&#xD;
&#xD;
          -  Previously treated with a JAK inhibitor and failed on a JAK inhibitor or are&#xD;
             ineligible to be treated with Ruxolitinib or Fedratinib at the discretion of the&#xD;
             investigator&#xD;
&#xD;
          -  Grade ≥ 2 bone marrow fibrosis, as confirmed by bone marrow biopsy within 12 weeks&#xD;
             prior to Screening&#xD;
&#xD;
        Fulfill the following laboratory parameters:&#xD;
&#xD;
          -  Platelet count ≥ 25 X 10^9 /L, without the assistance of growth factors or platelet&#xD;
             transfusions&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1 x 10^9/L without the assistance of granulocyte&#xD;
             growth factors&#xD;
&#xD;
          -  Peripheral blood blast count &lt; 10%&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate renal function, as determined by clinical laboratory tests (serum creatinine&#xD;
             ≤ 1.5 x upper limit of normal (ULN), and calculated creatinine clearance ≥ 30 mL/min)&#xD;
             (Cockcroft-Gault)&#xD;
&#xD;
          -  Adequate hepatic function (ALT/AST ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN; or ALT/AST&#xD;
             ≤ 5 x ULN, direct bilirubin ≤ 2 x ULN if due to myelofibrosis), and coagulation ([PT&#xD;
             and PTT] ≤ 1.5 x ULN)&#xD;
&#xD;
          -  Agree to provide bone marrow biopsies during the study: at baseline or within 12 weeks&#xD;
             prior to enrollment, and every 6 months during treatment.&#xD;
&#xD;
          -  Splenomegaly during the screening period as demonstrated by splenic length ≥ 5 cm&#xD;
             below the costal margin by palpation or spleen volume of ≥ 450 cm3 by Magnetic&#xD;
             Resonance Imaging (MRI) or Computerized Tomography (CT) scan&#xD;
&#xD;
          -  Show at least 2 symptoms measurable (score ≥ 1) using the MF-SAF, v4.0.&#xD;
&#xD;
        Patients meeting any one of these exclusion criteria will be prohibited from participating&#xD;
        in this study:&#xD;
&#xD;
          -  Received previous systemic antineoplastic therapy (including unconjugated therapeutic&#xD;
             antibodies, toxin immunoconjugates, ESA, and alpha-interferon) or any experimental&#xD;
             therapy within 14 days or 5 half-lives, whichever is longer, before the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Major surgery within 2 weeks before the first dose of either study drug.&#xD;
&#xD;
          -  Splenic irradiation within 6 months prior to Screening or prior splenectomy.&#xD;
&#xD;
          -  AML, MDS, or peripheral blasts ≥ 10%.&#xD;
&#xD;
          -  Prior autologous or allogeneic stem cell transplant at any time.&#xD;
&#xD;
          -  Eligible for allogeneic bone marrow or stem cell transplantation within 3 months&#xD;
             following enrollment.&#xD;
&#xD;
          -  Experiencing electrolyte abnormalities of NCI CTCAE Grade ≥ 2 unless they can be&#xD;
             corrected during screening and are deemed not clinically significant by the&#xD;
             Investigator.&#xD;
&#xD;
          -  History of congestive heart failure, myocardial infarction within the past 6 months&#xD;
             prior to Cycle 1/Day 1; left ventricular ejection fraction &lt; 45% by echocardiogram or&#xD;
             MUGA, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG) within&#xD;
             14 days prior to Cycle 1/Day 1.&#xD;
&#xD;
          -  Corrected QT interval (using Fridericia's correction formula) of &gt; 450 msec in men and&#xD;
             &gt; 470 msec in women.&#xD;
&#xD;
          -  Central nervous system (CNS) cancer or metastases, meningeal carcinomatosis, malignant&#xD;
             seizures, or a disease that either causes or threatens neurologic compromise (eg,&#xD;
             unstable vertebral metastases).&#xD;
&#xD;
          -  Other invasive malignancies within the last 3 years, except non-melanoma skin cancer,&#xD;
             and localized cured prostate and cervical cancer&#xD;
&#xD;
          -  Experienced portal hypertension or any of its complications.&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             antimicrobial within 14 days.&#xD;
&#xD;
          -  Known bleeding diathesis or signs of uncontrolled active bleeding (hematuria, GI&#xD;
             bleeding) other than self-limited causes of benign etiology that have been adequately&#xD;
             investigated at the discretion of the Investigator.&#xD;
&#xD;
          -  Requiring anticoagulation with aspirin &gt; 81mg daily, unfractionated heparin, low&#xD;
             molecular weight heparin (LMWH), direct anti-thrombin inhibitors, or vitamin K&#xD;
             antagonists (eg, warfarin).&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease with hypoxemia (defined as resting O2&#xD;
             saturation of &lt; 90% breathing room air).&#xD;
&#xD;
          -  Medical condition or have undergone significant surgery to the gastrointestinal tract&#xD;
             that could impair absorption or that could result in short bowel syndrome with&#xD;
             diarrhea due to malabsorption.&#xD;
&#xD;
          -  Used hydroxyurea or anagrelide within 24 hours prior to the first dose.&#xD;
&#xD;
          -  Systemic steroid therapy (&gt;10 mg daily prednisone or equivalent) within 7 days prior&#xD;
             to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic&#xD;
             steroids are not prohibited).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tegan Nguyen</last_name>
    <phone>617-674-8745</phone>
    <email>tegan.nguyen@sdponcology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judy Costas</last_name>
    <email>judy.costas@sdponcology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Health Shands Cancer Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sheehan</last_name>
      <phone>352-273-9148</phone>
      <email>sheehwd@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Borza</last_name>
      <phone>551-966-8017</phone>
      <email>michelle.borza@hmhn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Belko</last_name>
      <phone>716-845-3373</phone>
      <email>krista.belko@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally West</last_name>
      <phone>919-613-1482</phone>
      <email>sally.west@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Reed</last_name>
      <phone>434-297-7783</phone>
      <email>yvy8ge@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

